| Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. A Elisabetta, P Guglielmelli, G Poli, B Costanza, P Alessandro, L Giovanni, ... Haematologica 93, 41-48, 2008 | 231 | 2008 |
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis P Guglielmelli, G Barosi, A Rambaldi, R Marchioli, A Masciulli, L Tozzi, ... Blood, The Journal of the American Society of Hematology 118 (8), 2069-2076, 2011 | 180 | 2011 |
| Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies CA Di Buduo, LS Wray, L Tozzi, A Malara, Y Chen, CE Ghezzi, D Smoot, ... Blood, The Journal of the American Society of Hematology 125 (14), 2254-2264, 2015 | 174 | 2015 |
| High‐strength, durable all‐silk fibroin hydrogels with versatile processability toward multifunctional applications Z Zhu, S Ling, J Yeo, S Zhao, L Tozzi, MJ Buehler, F Omenetto, C Li, ... Advanced functional materials 28 (10), 1704757, 2018 | 152 | 2018 |
| Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation V Rosti, L Villani, R Riboni, V Poletto, E Bonetti, L Tozzi, G Bergamaschi, ... Blood, The Journal of the American Society of Hematology 121 (2), 360-368, 2013 | 125 | 2013 |
| mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms C Bogani, N Bartalucci, S Martinelli, L Tozzi, P Guglielmelli, A Bosi, ... PLoS One 8 (1), e54826, 2013 | 113 | 2013 |
| Co‐targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms N Bartalucci, L Tozzi, C Bogani, S Martinelli, G Rotunno, JL Villeval, ... Journal of cellular and molecular medicine 17 (11), 1385-1396, 2013 | 110 | 2013 |
| The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control A Malara, V Abbonante, CA Di Buduo, L Tozzi, M Currao, A Balduini Cellular and molecular life sciences 72, 1517-1536, 2015 | 105 | 2015 |
| MicroRNA expression profile in granulocytes from primary myelofibrosis patients P Guglielmelli, L Tozzi, A Pancrazzi, C Bogani, E Antonioli, V Ponziani, ... Experimental hematology 35 (11), 1708. e1-1708. e12, 2007 | 104 | 2007 |
| Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia E Antonioli, A Carobbio, L Pieri, A Pancrazzi, P Guglielmelli, F Delaini, ... Haematologica 95 (8), 1435, 2010 | 58 | 2010 |
| Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production L Tozzi, PA Laurent, CA Di Buduo, X Mu, A Massaro, R Bretherton, ... Biomaterials 178, 122-133, 2018 | 56 | 2018 |
| The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. AM Vannucchi, C Bogani, N Bartalucci, P Guglielmelli, L Tozzi, E Antonioli, ... Blood 114 (22), 2914, 2009 | 55 | 2009 |
| RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia … AM Vannucchi, P Guglielmelli, E Gattoni, E Antonioli, C Bogani, L Tozzi, ... Blood 114 (22), 307, 2009 | 52 | 2009 |
| Inhibitors of PI3K/Akt and/or mTOR inhibit the growth of cells of myeloproliferative neoplasms and synergize with JAK2 inhibitor and interferon AM Vannucchi, C Bogani, N Bartalucci, L Tozzi, S Martinelli, ... Blood 118 (21), 3835, 2011 | 51 | 2011 |
| Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera P Guglielmelli, L Tozzi, C Bogani, I Iacobucci, V Ponziani, G Martinelli, ... Blood, The Journal of the American Society of Hematology 117 (25), 6923-6927, 2011 | 40 | 2011 |
| Modular flow chamber for engineering bone marrow architecture and function CA Di Buduo, PM Soprano, L Tozzi, S Marconi, F Auricchio, DL Kaplan, ... Biomaterials 146, 60-71, 2017 | 32 | 2017 |
| Hyaluronan based hydrogels provide an improved model to study megakaryocyte–matrix interactions M Currao, A Malara, CA Di Buduo, V Abbonante, L Tozzi, A Balduini Experimental cell research 346 (1), 1-8, 2016 | 31 | 2016 |
| Repetitive head injury in adolescent mice: A role for vascular inflammation L Wu, JY Chung, S Saith, L Tozzi, EM Buckley, B Sanders, ... Journal of Cerebral Blood Flow & Metabolism 39 (11), 2196-2209, 2019 | 26 | 2019 |
| A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results AM Vannucchi, P Guglielmelli, L Lupo, MC Finazzi, L Tozzi, F Biamonte, ... Blood 116 (21), 314, 2010 | 18 | 2010 |
| Genetic inhibition of RIPK3 ameliorates functional outcome in controlled cortical impact independent of necroptosis L Wu, JY Chung, T Cao, G Jin, WJ Edmiston III, S Hickman, ES Levy, ... Cell death & disease 12 (11), 1064, 2021 | 15 | 2021 |
